San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Replicate Bioscience is raising $53,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nathaniel Wang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Replicate Bioscience
Replicate harnesses the bodys natural protein-making power and uses synthetic biology to design unique self-replicating RNAs (srRNAs) that can direct that power to fight disease. With our customizable srRNA platform and our diverse repertoire of virally derived vectors, we are tackling drug resistance in cancers and discovering new treatments for autoimmune and inflammatory disorders and other diseases. Replicate is working to make srRNA therapeutics broadly accessible, to realize their promise for all patients.

To learn more about Replicate Bioscience, visit http://replicatebioscience.com/

Contact:
Nathaniel Wang, Chief Executive Officer
619-786-7702
nwang@replicatebioscience.com
https://www.linkedin.com/in/nathaniel-wang-32512a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved